Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 4/2011

01-12-2011 | Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Women and Vulnerability to HAART Non-Adherence: A Literature Review of Treatment Adherence by Gender from 2000 to 2011

Authors: Cathy M. Puskas, Jamie I. Forrest, Surita Parashar, Kate A. Salters, Angela M. Cescon, Angela Kaida, Cari L. Miller, David R. Bangsberg, Robert S. Hogg

Published in: Current HIV/AIDS Reports | Issue 4/2011

Login to get access

Abstract

A literature review of original research articles on adherence to antiretroviral therapy (ART) in developed countries, covering January 2000 to June 2011, was conducted to determine if gender differences exist in the prevalence of nonadherence to ART. Of the 1,255 articles reviewed, only 189 included data on the proportion of the study population that was adherent and only 57 (30.2%) of these reported proportional adherence values by gender. While comparing articles was challenging because of varied reporting strategies, women generally exhibit poorer adherence than men. Thirty of the 44 articles (68.2%) that reported comparative data on adherence by gender found women to be less adherent than men. Ten articles (17.5%) reported significant differences in proportional adherence by gender, nine of which showed women to be less adherent than men. These findings suggest that in multiple studies from developed countries, female gender often predicts lower adherence. The unique circumstances of HIV–positive women require specialized care to increase adherence to ART.
Literature
1.
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMed
2.
Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8:282–92.PubMedCrossRef
3.
Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis. 2009;49:1433–40.PubMedCrossRef
4.
Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84:188–94.PubMedCrossRef
5.
Sullivan PS, Campsmith ML, Nakamura GV, et al. Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy. PLoS One. 2007;6:e552.CrossRef
6.
Parsons JT, Rosof E, Mustanski B. Patient-related factors predicting HIV medication adherence among men and women with alcohol problems. J Health Psychol. 2007;12:357–70.PubMedCrossRef
7.
McDonnell Holstad MK, Pace JC, Anindya K, et al. Factors associated with adherence to antiretroviral therapy. J Assoc Nurses AIDS Care. 2006;17:4–15.CrossRef
8.
Kuyper LM, Wood E, Montaner JSG, et al. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J Acquir Immune Defic Syndr. 2004;37:1470–6.PubMedCrossRef
9.
• Kacanek D, Jacobson DL, Spiegelman D, et al. Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2010;53:266–72. This study showed a significant relationship between incident depression and suboptimal ART adherence. A significantly higher proportion of women than men developed depressive symptoms and were less likely to be adherent. PubMedCrossRef
10.
Kumar V, Encinosa W. Effects of antidepressant treatment on antiretroviral regimen adherence among depressed HIV-infected patients. Psychiatr Q. 2009;80:131–41.PubMedCrossRef
11.
Lima VD, Geller J, Bangsberg DR, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007;21:1175–83.PubMedCrossRef
12.
Sledjeski EM, Delahanty DL, Bogart LM. Incidence and impact of posttraumatic stress disorder and comorbid depression on adherence to HAART and CD4+ counts in people living with HIV. AIDS Patient Care STDS. 2005;19:728–36.PubMedCrossRef
13.
Phillips KD, Moneyham L, Murdaugh C, et al. Sleep disturbance and depression as barriers to adherence. Clin Nurs Res. 2005;14:273–93.PubMedCrossRef
14.
Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45:394–402.PubMedCrossRef
15.
Gonzalez JS, Penedo FJ, Antoni MH, et al. Social support, positive states of mind, and HIV treatment adherence in men and women living with HIV/AIDS. Health Psychol. 2004;23:413–8.PubMedCrossRef
16.
Fielden SJ, Rusch MLA, Yip B, et al. Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naïve patients started on HAART. J Int Assoc Physicians AIDS Care. 2008;7:238–44.CrossRef
17.
•• Ubbiali A, Donati D, Chiorri C, et al. Prediction of adherence to antiretroviral therapy: can patients’ gender play some role? An Italian pilot study. AIDS Care 2008;20:571–5. This study examines the psychological characteristics of both non-adherent and adherent men and women, with a focus on relational style. Differences between genders were observed, with non-adherent women having a greater preoccupation with relationships and need for approval, while non-adherent men were found to be less relationship-oriented. PubMedCrossRef
18.
Sayles JN, Wong MD, Kinsler JJ, et al. The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS. J Gen Intern Med. 2009;24:1101–8.PubMedCrossRef
19.
Rintamaki LS, Davic TC, Skripkauskas S, et al. Social stigma concerns and HIV medication adherence. AIDS Patient Care STDS. 2006;20:359–68.PubMedCrossRef
20.
Leserman J, Ironson G, O’Cleirigh C, et al. Stressful life events and adherence to HIV. AIDS Patient Care STDS. 2008;22:403–11.PubMedCrossRef
21.
Wood SA, Tobias C, McCree J. Medication adherence for HIV positive women caring for children: in their own words. AIDS Care. 2004;16:909–13.PubMedCrossRef
22.
Mugavero MJ, Raper JL, Reif S, et al. Overload: impact of incident stressful events on antiretroviral medication adherence and virologic failure in a longitudinal, multisite human immunodeficiency virus cohort study. Psychosom Med. 2009;9:920–6.CrossRef
23.
Shin S, Muñoz M, Espiritu B, et al. Psychosocial impact of poverty on antiretroviral nonadherence among HIV-TB coinfected patients in Lima, Peru. J Int Assoc Physicians AIDS Care. 2008;7:74–81.CrossRef
24.
Knowlton AR, Arnsten JH, Eldred LJ, et al. Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors. AIDS Patient Care STDS. 2010;24:421–8.PubMedCrossRef
25.
Pulvirenti JJ, Glowacki R, Muppiddi U, et al. Hospitalized HIV-infected patients in the HAART era: a view from the inner city. AIDS Patient Care STDS. 2003;17:565–73.PubMedCrossRef
26.
Moore DM, Zhang W, Genebat M, et al. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med. 2010;11:299–307.PubMedCrossRef
27.
Carmody ER, Diaz T, Starling P, et al. An evaluation of antiretroviral HIV/AIDS treatment in a Rio de Janeiro public clinic. Trop Med Int Health. 2003;8:378–85.PubMedCrossRef
28.
Yuan Y, L’Italien G, Mukherjee J, et al. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med. 2006;7:156–62.PubMedCrossRef
29.
Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55:460–5.PubMedCrossRef
30.
Jhaveri MA, Browning SR, Bush H, et al. Comparison of 3-drug versus 4 drug and PI versus non-PI combinations as initial HAART: experience from 1998 to 2007. J Int Assoc Physicians AIDS Care. 2009;8:299–307.CrossRef
31.
Turner BJ, Laine C, Cosler L, et al. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med. 2003;18:248–57.PubMedCrossRef
32.
Applebaum AJ, Richardson MA, Brady SM, et al. Gender and other psychosocial factors as predictors of adherence to highly active antiretroviral therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substance-related disorder. AIDS Behav. 2009;13:60–5.PubMedCrossRef
33.
Sherr L, Lampe F, Norwood S, et al. Successive switching of antiretroviral therapy is associated with high psychological and physical burden. Int J STD AIDS. 2007;18:700–4.PubMedCrossRef
34.
Wood E, Hogg RS, Yip B, et al. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≥200 cells/μl. AIDS. 2006;20:1117–23.PubMedCrossRef
35.
Barfod TS, Gerstoft J, Rodkjaer L, et al. Patients’ answers to simple questions about treatment satisfaction and adherence and depression are associated with failure of HAART: a cross-sectional survey. AIDS Patient Care STDS. 2005;19:317–25.PubMedCrossRef
36.
Carrieri MP, Raffi F, Lewden C, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther. 2003;8:585–94.PubMed
37.
Roca B, Gómez CJ, Arnedo A. A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir in treatment-experienced HIV-infected patients. AIDS. 2000;14:157–61.PubMedCrossRef
38.
Simoni JM, Pantalone DW, Plummer MD, Huang B. A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women. Health Psychol. 2007;26:488–95.PubMedCrossRef
39.
Remien RH, Bastos FI, Terto Jr V, et al. Adherence to antiretroviral therapy in a context of universal access, in Rio de Janeiro, Brazil. AIDS Care. 2007;19:740–8.PubMedCrossRef
40.
Johnson MO, Charlebois E, Morin SF, et al. Perceived adverse effects of antiretroviral therapy. J Pain Symptom Manage. 2005;29:193–205.PubMedCrossRef
41.
Bouhnik A-D, Chesney M, Carrieri P, et al. Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr. 2002;31:S149–53.PubMedCrossRef
42.
Sherr L, Lampe FC, Clucas C, et al. Self-reported non-adherence to ART and virological outcome in a multiclinic UK study. AIDS Care. 2010;22:939–45.PubMedCrossRef
43.
44.
Kerr T, Walsh J, Lloyd-Smith E, Wood E. Measuring adherence to highly active antiretroviral therapy: implications for research and practice. Curr HIV/AIDS Rep. 2005;2:200–5.PubMedCrossRef
45.
46.
Kyser M, Buchacz K, Bush TJ, et al. Factors associated with non-adherence to antiretroviral therapy in the SUN study. AIDS Care. 2011;23:601–11.PubMedCrossRef
47.
Royal SW, Kidder DP, Patrabansh S, et al. Factors associated with adherence to highly active antiretroviral therapy in homeless or unstably housed adults living with HIV. AIDS Care. 2009;21:448–55.PubMedCrossRef
48.
Miguez-Burbano MJ, Espinoza L, Lewis JE. HIV treatment adherence and sexual functioning. AIDS Behav. 2008;12:78–85.PubMedCrossRef
49.
Sherr L, Lampe F, Norwood S, et al. Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care. 2008;20:442–8.PubMedCrossRef
50.
Beach MC, Duggan PS, Moore RD. Is patients’ preferred involvement in health decisions related to outcomes for patients with HIV? J Gen Intern Med. 2007;22:1119–24.PubMedCrossRef
51.
Peretti-Watel P, Spire B, Lert F, et al. Drug use patterns and adherence to treatment among HIV-positive patients: evidence from a large sample of French outpatients (ANRS-EN12-VESPA 2003). Drug Alcohol Depend. 2006;82:S71–9.PubMedCrossRef
52.
Peretti-Watel P, Spire B, Schiltz MA, et al. Vulnerability, unsafe sex and non-adherence to HAART: evidence from a large sample of French HIV/AIDS outpatients. Soc Sci Med. 2006;62:2420–33.PubMedCrossRef
53.
Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health. 2004;94:1133–40.PubMedCrossRef
54.
Deloria-Knoll M, Chmiel JS, Moorman AC, et al. Factors related to and consequences of adherence to antiretroviral therapy in an ambulatory HIV-infected patient cohort. AIDS Patient Care STDS. 2004;18:721–7.PubMedCrossRef
55.
Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS. 2004;18:683–8.PubMedCrossRef
56.
Palepu A, Tyndall MW, Chan K, et al. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther. 2004;9:713–9.PubMed
57.
Sharpe TT, Lee LM, Nakashima AK, et al. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health. 2004;29:117–27.PubMedCrossRef
58.
Fong OW, Ho CF, Fung LY, et al. Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Med. 2003;4:133–8.PubMedCrossRef
59.
Spire B, Duran S, Souville M, et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54:1481–96.PubMedCrossRef
60.
Wagner GJ, Remien RH, Carballo-Diéguez A, Dolezal C. Correlates of adherence to combination antiretroviral therapy among members of HIV-positive mixed status couples. AIDS Care. 2002;14:105–9.PubMedCrossRef
61.
Brigido LFM, Rodrigues R, Casseb J, et al. Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. AIDS Patient Care STDS. 2001;15:587–93.PubMedCrossRef
62.
Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor on HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2:38–45.PubMedCrossRef
63.
Gross R, Yip B, Re LR, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;15:1108–14.CrossRef
64.
Plankey M, Bacchetti P, Chengshi J, et al. Self-perception of body fat changes and HAART adherence in the Women’s Interagency HIV Study. AIDS Behav. 2009;13:53–9.PubMedCrossRef
65.
Fumaz CR, Muñoz-Moreno JA, Moltó J, et al. Sustained antiretroviral treatment adherence in survivors of the pre-HAART era: attitudes and beliefs. AIDS Care. 2008;20:796–805.PubMedCrossRef
66.
Kapadia F, Vlahov D, Wu Y, et al. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am J Drug Alcohol Abuse. 2008;34:161–70.PubMedCrossRef
67.
Merenstein DJ, Schneider MF, Cox C, et al. Association between living with children and adherence to highly active antiretroviral therapy in the Women’s Interagency HIV Study. Pediatrics. 2008;121:e787–93.PubMedCrossRef
68.
Graham J, Bennett IM, Holmes WC, Gross R. Medication beliefs as mediators of the health literacy-antiretroviral adherence relationship in HIV infected individuals. AIDS Behav. 2007;11:385–92.PubMedCrossRef
69.
Vaz MJR, Barros SMO, Palacios R, et al. HIV-infected pregnant women have greater adherence with antiretroviral drugs than non-pregnant women. Int J STD AIDS. 2007;18:28–32.PubMedCrossRef
70.
Braitstein P, Justice A, Bangsberg DR, et al. Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS. 2006;20:323–31.PubMedCrossRef
71.
Södergård B, Halvarsson M, Tully MP, et al. Adherence to treatment in Swedish HIV-infected patients. J Clin Pharm Ther. 2006;31:605–15.PubMedCrossRef
72.
Anastos K, Schneider MF, Gange SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005;39:537–44.PubMed
73.
de Bonolo PF, César CC, Acúrcio FA, et al. Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. AIDS. 2005;19:S5–13.CrossRef
74.
Halkitis PN, Kutnick AH, Slater S. The social realities of adherence to protease inhibitor regimens: substance use, health care and psychological states. J Health Psychol. 2005;10:545–58.PubMedCrossRef
75.
Kerr T, Palepu A, Barnes G, et al. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antivir Ther. 2004;9:407–14.PubMed
76.
Mohammed H, Kieltyka L, Richardson-Alston G, et al. Adherence to HAART among HIV-infected persons in rural Louisiana. AIDS Patient Care STDS. 2004;18:289–96.PubMedCrossRef
77.
Palepu A, Horton NJ, Tibbetts N, et al. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction. 2004;99:361–8.PubMedCrossRef
78.
Delgado J, Heath KV, Yip B, et al. Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill. Antivir Ther. 2003;8:471–8.PubMed
79.
Parruti G, Manzoli L, Toro PM, et al. Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDS. 2006;20:48–57.PubMedCrossRef
80.
García de Olalla P, Knobel H, Carmona A, et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30:105–10.PubMed
81.
Witteveen E, van Ameijden EJC. Drug users and HIV-combination therapy (HAART): factors which impede or facilitate adherence. Subst Use Misuse. 2002;37:1905–25.PubMedCrossRef
82.
Martín J, Escobar I, Rubio R, et al. Study of the validity of a questionnaire to assess the adherence to therapy in patients infected by HIV. HIV Clin Trials. 2001;2:31–7.PubMedCrossRef
83.
Moatti JP, Carrieri MP, Spire B, et al. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS. 2000;14:151–5.PubMedCrossRef
84.
Duggan JM, Locher A, Fink B, et al. Adherence to antiretroviral therapy: a survey of factors associated with medication usage. AIDS Care. 2009;21:1141–7.PubMedCrossRef
85.
Cardarelli R, Weis S, Adams E, et al. General health status and adherence to antiretroviral therapy. J Int Assoc Physicians AIDS Care. 2008;7:123–9.CrossRef
86.
Garcia R, Badaró R, Netto EM, et al. Cross-sectional study to evaluate factors associated with adherence to antiretroviral therapy by Brazilian HIV-infected patients. AIDS Res Hum Retroviruses. 2006;22:1248–52.PubMedCrossRef
87.
Moralejo L, Inés S, Marcos M, et al. Factors influencing adherence to highly active antiretroviral therapy in Spain. Curr HIV Res. 2006;4:221–7.PubMedCrossRef
88.
Russell J, Krantz S, Neville S. The patient-provider relationship and adherence to highly active antiretroviral therapy. J Assoc Nurses AIDS Care. 2004;15:40–7.PubMedCrossRef
89.
Haug NA, Sorensen JL, Lollo ND, et al. Gender differences among HIV-positive methadone maintenance patients enrolled in a medication adherence trial. AIDS Care. 2005;17:1022–9.PubMedCrossRef
90.
Sidat M, Fairley C, Grierson J. Experiences and perceptions of patients with 100% adherence to highly active antiretroviral therapy: a qualitative study. AIDS Patient Care STDS. 2007;21:509–20.PubMedCrossRef
91.
Ware NC, Wyatt MA, Tugenberg T. Social relationships, stigma and adherence to antiretroviral therapy for HIV/AIDS. AIDS Care. 2006;18:904–10.PubMedCrossRef
92.
Stevens PE, Hildebrandt E. Pill taking from the perspective of HIV-infected women who are vulnerable to antiretroviral treatment failure. Qual Health Res. 2009;19:593–604.PubMedCrossRef
93.
Lewis MP, Colbert A, Erlen J, Meyers M. A qualitative study of persons who are 100% adherent to antiretroviral therapy. AIDS Care. 2006;18:140–8.
Metadata
Title
Women and Vulnerability to HAART Non-Adherence: A Literature Review of Treatment Adherence by Gender from 2000 to 2011
Authors
Cathy M. Puskas
Jamie I. Forrest
Surita Parashar
Kate A. Salters
Angela M. Cescon
Angela Kaida
Cari L. Miller
David R. Bangsberg
Robert S. Hogg
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 4/2011
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-011-0098-0

Other articles of this Issue 4/2011

Current HIV/AIDS Reports 4/2011 Go to the issue

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Neurocognitive Impact of Antiretroviral Treatment: Thinking Long-Term

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Secondary HIV Prevention: Novel Intervention Approaches to Impact Populations Most at Risk

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

HIV-Related Research in Correctional Populations: Now is the Time

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Substance Use: Impact on Adherence and HIV Medical Treatment

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

A Global Perspective on Complementary and Alternative Medicine Use Among People Living with HIV/AIDS in the Era of Antiretroviral Treatment

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Link to Slower Access to Care: What is the Stigma? An Indian Perspective
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits